Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Preclinical Evaluation of 68Ga-DOTA-NT-20.3: A Promising PET Imaging Probe To Discriminate Human Pancreatic Ductal Adenocarcinoma from Pancreatitis.

Prignon A, Provost C, Alshoukr F, Wendum D, Couvelard A, Barbet J, Forgez P, Talbot JN, Gruaz-Guyon A.

Mol Pharm. 2019 Jun 3;16(6):2776-2784. doi: 10.1021/acs.molpharmaceut.9b00283. Epub 2019 May 3.

PMID:
31013092
2.

Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibody.

Wu Z, Fournel L, Stadler N, Liu J, Boullier A, Hoyeau N, Fléjou JF, Duchatelle V, Djebrani-Oussedik N, Agopiantz M, Ségal-Bendirdjian E, Gompel A, Alifano M, Melander O, Trédaniel J, Forgez P.

Cancer Lett. 2019 Mar 1;444:147-161. doi: 10.1016/j.canlet.2018.12.007. Epub 2018 Dec 21.

PMID:
30583074
3.

Expression of neurotensin receptor 1 in endometrial adenocarcinoma is correlated with histological grade and clinical outcome.

Agopiantz M, Forgez P, Casse JM, Lacomme S, Charra-Brunaud C, Clerc-Urmès I, Morel O, Bonnet C, Guéant JL, Vignaud JM, Gompel A, Gauchotte G.

Virchows Arch. 2017 Oct;471(4):521-530. doi: 10.1007/s00428-017-2215-y. Epub 2017 Aug 24.

PMID:
28836043
4.

Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer.

Liu J, Agopiantz M, Poupon J, Wu Z, Just PA, Borghese B, Ségal-Bendirdjian E, Gauchotte G, Gompel A, Forgez P.

Clin Cancer Res. 2017 Nov 1;23(21):6516-6528. doi: 10.1158/1078-0432.CCR-17-0861. Epub 2017 Aug 8.

5.

Neurotensin regulation induces overexpression and activation of EGFR in HCC and restores response to erlotinib and sorafenib.

Wu Z, Galmiche A, Liu J, Stadler N, Wendum D, Segal-Bendirdjian E, Paradis V, Forgez P.

Cancer Lett. 2017 Mar 1;388:73-84. doi: 10.1016/j.canlet.2016.11.032. Epub 2016 Dec 1.

PMID:
27914862
6.

Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.

Communal L, Vilasco M, Hugon-Rodin J, Courtin A, Mourra N, Lahlou N, Le Guillou M, Perrault de Jotemps M, Chauvet MP, Chaouat M, Pujol P, Feunteun J, Delaloge S, Forgez P, Gompel A.

Oncotarget. 2016 Jul 19;7(29):45317-45330. doi: 10.18632/oncotarget.9638.

7.

Erratum to: Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue.

Vilasco M, Communal L, Hugon-Rodin J, Penault-Llorca F, Mourra N, Wu Z, Forgez P, Gompel A; BRACAPS.

Breast Cancer Res Treat. 2016 Apr;156(2):401-2. doi: 10.1007/s10549-016-3712-4.

PMID:
26956972
8.

Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial.

Mote PA, Gompel A, Howe C, Hilton HN, Sestak I, Cuzick J, Dowsett M, Hugol D, Forgez P, Byth K, Graham JD, Clarke CL.

Breast Cancer Res Treat. 2015 Jun;151(2):309-18. doi: 10.1007/s10549-015-3397-0. Epub 2015 Apr 28.

PMID:
25917868
9.

Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.

Younes M, Wu Z, Dupouy S, Lupo AM, Mourra N, Takahashi T, Fléjou JF, Trédaniel J, Régnard JF, Damotte D, Alifano M, Forgez P.

Oncotarget. 2014 Sep 30;5(18):8252-69.

10.

Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.

Dupouy S, Doan VK, Wu Z, Mourra N, Liu J, De Wever O, Llorca FP, Cayre A, Kouchkar A, Gompel A, Forgez P.

Oncotarget. 2014 Sep 30;5(18):8235-51.

11.

Suicide HSVtk gene delivery by neurotensin-polyplex nanoparticles via the bloodstream and GCV Treatment specifically inhibit the growth of human MDA-MB-231 triple negative breast cancer tumors xenografted in athymic mice.

Castillo-Rodríguez RA, Arango-Rodríguez ML, Escobedo L, Hernandez-Baltazar D, Gompel A, Forgez P, Martínez-Fong D.

PLoS One. 2014 May 13;9(5):e97151. doi: 10.1371/journal.pone.0097151. eCollection 2014.

12.

Safety of the intravenous administration of neurotensin-polyplex nanoparticles in BALB/c mice.

Hernandez ME, Rembao JD, Hernandez-Baltazar D, Castillo-Rodriguez RA, Tellez-Lopez VM, Flores-Martinez YM, Orozco-Barrios CE, Rubio HA, Sánchez-García A, Ayala-Davila J, Arango-Rodriguez ML, Pavón L, Mejia-Castillo T, Forgez P, Martinez-Fong D.

Nanomedicine. 2014 May;10(4):745-54. doi: 10.1016/j.nano.2013.11.013. Epub 2013 Dec 10.

PMID:
24333586
13.

Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue.

Vilasco M, Communal L, Hugon-Rodin J, Penault-Llorca F, Mourra N, Wu Z, Forgez P, Gompel A; BRACAPS.

Breast Cancer Res Treat. 2013 Nov;142(2):283-96. doi: 10.1007/s10549-013-2722-8. Epub 2013 Oct 29. Erratum in: Breast Cancer Res Treat. 2016 Apr;156(2):401-2.

PMID:
24166279
14.

Reply to the editor.

Baud M, Forgez P, Damotte D, Alifano M.

J Thorac Cardiovasc Surg. 2013 Oct;146(4):990-1. doi: 10.1016/j.jtcvs.2013.05.021. No abstract available.

15.

Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy.

Wu Z, Martinez-Fong D, Trédaniel J, Forgez P.

Front Endocrinol (Lausanne). 2013 Jan 17;3:184. doi: 10.3389/fendo.2012.00184. eCollection 2012.

16.

Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis.

Baud M, Strano S, Dechartres A, Jouni R, Triponez F, Chouaid C, Forgez P, Damotte D, Roche N, Régnard JF, Alifano M.

J Thorac Cardiovasc Surg. 2013 May;145(5):1305-11. doi: 10.1016/j.jtcvs.2012.09.023. Epub 2012 Oct 13.

17.

Ulipristal acetate does not impact human normal breast tissue.

Communal L, Vilasco M, Hugon-Rodin J, Courtin A, Mourra N, Lahlou N, Dumont S, Chaouat M, Forgez P, Gompel A.

Hum Reprod. 2012 Sep;27(9):2785-98. doi: 10.1093/humrep/des221. Epub 2012 Jun 26.

PMID:
22740493
18.

Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer.

Alifano M, Falcoz PE, Seegers V, Roche N, Schussler O, Younes M, Antonacci F, Forgez P, Dechartres A, Massard G, Damotte D, Régnard JF.

J Thorac Cardiovasc Surg. 2011 Nov;142(5):1161-7. doi: 10.1016/j.jtcvs.2011.07.021. Epub 2011 Aug 26.

19.

Glucocorticoid receptor and breast cancer.

Vilasco M, Communal L, Mourra N, Courtin A, Forgez P, Gompel A.

Breast Cancer Res Treat. 2011 Nov;130(1):1-10. doi: 10.1007/s10549-011-1689-6. Epub 2011 Aug 5. Review.

PMID:
21818591
20.

The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers.

Dupouy S, Mourra N, Doan VK, Gompel A, Alifano M, Forgez P.

Biochimie. 2011 Sep;93(9):1369-78. doi: 10.1016/j.biochi.2011.04.024. Epub 2011 May 17. Review.

PMID:
21605619
21.

Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells.

Courtin A, Communal L, Vilasco M, Cimino D, Mourra N, de Bortoli M, Taverna D, Faussat AM, Chaouat M, Forgez P, Gompel A.

Breast Cancer Res Treat. 2012 Jan;131(1):49-63. doi: 10.1007/s10549-011-1394-5. Epub 2011 Feb 19.

PMID:
21336598
22.

Neurotensin receptor 1 determines the outcome of non-small cell lung cancer.

Alifano M, Souazé F, Dupouy S, Camilleri-Broët S, Younes M, Ahmed-Zaïd SM, Takahashi T, Cancellieri A, Damiani S, Boaron M, Broët P, Miller LD, Gespach C, Regnard JF, Forgez P.

Clin Cancer Res. 2010 Sep 1;16(17):4401-10. doi: 10.1158/1078-0432.CCR-10-0659.

23.

Neurotensin expression and outcome of malignant pleural mesothelioma.

Alifano M, Loi M, Camilleri-Broet S, Dupouy S, Régnard JF, Forgez P.

Biochimie. 2010 Feb;92(2):164-70. doi: 10.1016/j.biochi.2009.11.004. Epub 2009 Nov 20.

PMID:
19932148
24.

Progestins induce catalase activities in breast cancer cells through PRB isoform: correlation with cell growth inhibition.

Petit E, Courtin A, Kloosterboer HJ, Rostène W, Forgez P, Gompel A.

J Steroid Biochem Mol Biol. 2009 Jul;115(3-5):153-60. doi: 10.1016/j.jsbmb.2009.04.002. Epub 2009 Apr 19.

PMID:
19383545
25.

NT-polyplex: a new tool for therapeutic gene delivery to neuroblastoma tumors.

Rubio-Zapata HA, Rembao-Bojorquez JD, Arango-Rodriguez ML, Dupouy S, Forgez P, Martinez-Fong D.

Cancer Gene Ther. 2009 Jul;16(7):573-84. doi: 10.1038/cgt.2009.1. Epub 2009 Jan 30.

PMID:
19180142
26.

The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression.

Dupouy S, Viardot-Foucault V, Alifano M, Souazé F, Plu-Bureau G, Chaouat M, Lavaur A, Hugol D, Gespach C, Gompel A, Forgez P.

PLoS One. 2009;4(1):e4223. doi: 10.1371/journal.pone.0004223. Epub 2009 Jan 19.

27.

Over-expression of neurotensin high-affinity receptor 1 (NTS1) in relation with its ligand neurotensin (NT) and nuclear beta-catenin in inflammatory bowel disease-related oncogenesis.

Bossard C, Souazé F, Jarry A, Bezieau S, Mosnier JF, Forgez P, Laboisse CL.

Peptides. 2007 Oct;28(10):2030-5. Epub 2007 Jul 25.

PMID:
17870207
28.

Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Galpha/Gbetagamma protein complex.

Prévost GP, Lonchampt MO, Holbeck S, Attoub S, Zaharevitz D, Alley M, Wright J, Brezak MC, Coulomb H, Savola A, Huchet M, Chaumeron S, Nguyen QD, Forgez P, Bruyneel E, Bracke M, Ferrandis E, Roubert P, Demarquay D, Gespach C, Kasprzyk PG.

Cancer Res. 2006 Sep 15;66(18):9227-34.

29.

Molecular and cellular regulation of neurotensin receptor under acute and chronic agonist stimulation.

Souazé F, Forgez P.

Peptides. 2006 Oct;27(10):2493-501. Epub 2006 Aug 4. Review.

PMID:
16889873
30.

Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression.

Souazé F, Dupouy S, Viardot-Foucault V, Bruyneel E, Attoub S, Gespach C, Gompel A, Forgez P.

Cancer Res. 2006 Jun 15;66(12):6243-9.

31.

Biophysical characteristics of neurotensin polyplex for in vitro and in vivo gene transfection.

Arango-Rodriguez ML, Navarro-Quiroga I, Gonzalez-Barrios JA, Martinez-Arguelles DB, Bannon MJ, Kouri J, Forgez P, Rostene W, Garcia-Villegas R, Jimenez I, Martinez-Fong D.

Biochim Biophys Acta. 2006 Jul;1760(7):1009-20. Epub 2006 Apr 3.

PMID:
16730907
32.

Neurotensin receptor 1 gene activation by the Tcf/beta-catenin pathway is an early event in human colonic adenomas.

Souazé F, Viardot-Foucault V, Roullet N, Toy-Miou-Leong M, Gompel A, Bruyneel E, Comperat E, Faux MC, Mareel M, Rostène W, Fléjou JF, Gespach C, Forgez P.

Carcinogenesis. 2006 Apr;27(4):708-16. Epub 2005 Nov 19.

PMID:
16299383
33.

Steroidal hormones and proliferation, differentiation and apoptosis in breast cells.

Gompel A, Chaouat M, Hugol D, Forgez P.

Maturitas. 2004 Sep 24;49(1):16-24. Review.

PMID:
15351092
34.

NT agonist regulates expression of nuclear high-affinity neurotensin receptors.

Toy-Miou-Leong M, Bachelet CM, Pélaprat D, Rostène W, Forgez P.

J Histochem Cytochem. 2004 Mar;52(3):335-45.

PMID:
14966200
36.

Differential involvement of intracellular domains of the rat NTS1 neurotensin receptor in coupling to G proteins: a molecular basis for agonist-directed trafficking of receptor stimulus.

Skrzydelski D, Lhiaubet AM, Lebeau A, Forgez P, Yamada M, Hermans E, Rostene W, Pelaprat D.

Mol Pharmacol. 2003 Aug;64(2):421-9.

PMID:
12869647
37.

Antiestrogens are pro-apoptotic in normal human breast epithelial cells.

Somaï S, Chaouat M, Jacob D, Perrot JY, Rostène W, Forgez P, Gompel A.

Int J Cancer. 2003 Jul 10;105(5):607-12.

38.

Neurotensin induces tyrosine hydroxylase gene activation through nitric oxide and protein kinase C signaling pathways.

Najimi M, Robert JJ, Mallet J, Rostène W, Forgez P.

Mol Pharmacol. 2002 Sep;62(3):647-53.

PMID:
12181441
39.

Neurotensin counteracts apoptosis in breast cancer cells.

Somaï S, Gompel A, Rostène W, Forgez P.

Biochem Biophys Res Commun. 2002 Jul 12;295(2):482-8.

PMID:
12150975
40.

Expression of neurotensin receptors in human corneal keratocytes.

Bourcier T, Rondeau N, Paquet S, Forgez P, Lombet A, Pouzaud F, Rostène W, Borderie V, Laroche L.

Invest Ophthalmol Vis Sci. 2002 Jun;43(6):1765-71.

PMID:
12036977
41.

Europium-labeled epidermal growth factor and neurotensin: novel probes for receptor-binding studies.

Mazor O, Hillairet de Boisferon M, Lombet A, Gruaz-Guyon A, Gayer B, Skrzydelsky D, Kohen F, Forgez P, Scherz A, Rostene W, Salomon Y.

Anal Biochem. 2002 Feb 1;301(1):75-81.

PMID:
11811969
42.

Transcriptional regulation of the tyrosine hydroxylase gene by neurotensin in human neuroblastoma CHP212 cells.

Najimi M, Hermans E, Rostène W, Forgez P.

Metab Brain Dis. 2001 Dec;16(3-4):165-74.

PMID:
11769329
43.

Apoptosis and aging: breast cells and apoptosis.

Gompel A, Levy D, Chaouat M, Forgez P, Rostène W.

Maturitas. 2001 Feb 28;38(1):39-44. Review. No abstract available.

PMID:
11311585
44.

Hormonal regulation of apoptosis in breast cells and tissues.

Gompel A, Somaï S, Chaouat M, Kazem A, Kloosterboer HJ, Beusman I, Forgez P, Mimoun M, Rostène W.

Steroids. 2000 Oct-Nov;65(10-11):593-8. Review.

PMID:
11108864
45.

Regulation of human corneal epithelial cell proliferation and apoptosis by dexamethasone.

Bourcier T, Forgez P, Borderie V, Scheer S, Rostène W, Laroche L.

Invest Ophthalmol Vis Sci. 2000 Dec;41(13):4133-41.

PMID:
11095606
46.

In vitro effects of dexamethasone on human corneal keratocytes.

Bourcier T, Borderie V, Forgez P, Lombet A, Rostène W, Laroche L.

Invest Ophthalmol Vis Sci. 1999 May;40(6):1061-70.

PMID:
10235539
47.

Activation of receptor gene transcription is required to maintain cell sensitization after agonist exposure. Study on neurotensin receptor.

Najimi M, Souazé F, Méndez M, Hermans E, Berbar T, Rostène W, Forgez P.

J Biol Chem. 1998 Aug 21;273(34):21634-41.

48.
49.

High affinity neurotensin receptor mRNA distribution in rat brain and peripheral tissues. Analysis by quantitative RT-PCR.

Méndez M, Souazé F, Nagano M, Kelly PA, Rostène W, Forgez P.

J Mol Neurosci. 1997 Oct;9(2):93-102.

PMID:
9407390

Supplemental Content

Loading ...
Support Center